From familial combined hyperlipidemia to hyperapoB: unravelling the overproduction of hepatic apolipoprotein B

Abstract

Familial combined hyperlipidemia has so far been defined by the presence of multiple lipoprotein phenotypes within a family. We suggest that the hallmark of the syndrome is overproduction of hepatic apolipoprotein (apo)B resulting in an elevated plasma apoB and that therefore the syndrome should be renamed hyperapoB. Reasons for this proposal are reviewed as well as recent studies of the pathogenesis and therapy of hyperapoB.